Do urolithin A supplements cause harmful effects in humans?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Urolithin A Supplements Are Safe in Humans

Based on current evidence, urolithin A supplements do not cause harmful effects in humans and demonstrate a favorable safety profile across multiple clinical trials. 1, 2, 3

Safety Evidence from Clinical Trials

The most comprehensive safety data comes from multiple randomized controlled trials in humans:

  • Doses tested: 10-1000 mg/day for durations ranging from 28 days to 4 months 1
  • Population studied: 250+ healthy individuals, primarily middle-aged and older adults (ages 65-90 years) 2, 3
  • Adverse events: Only mild or moderate events that were unrelated to urolithin A supplementation 1, 2

A first-in-human clinical trial specifically established that urolithin A has a favorable safety profile as its primary outcome, with bioavailability confirmed in plasma at all tested doses 3. The largest randomized clinical trial (66 participants over 4 months) found no statistical differences in adverse events between urolithin A and placebo groups 2.

Documented Biological Effects

Urolithin A supplementation produces several measurable effects without causing harm:

  • Anti-inflammatory effects: Dose-dependent reduction in C-reactive protein and inflammatory markers 1, 2
  • Mitochondrial health: Upregulation of mitochondrial genes and markers of autophagy 1, 3
  • Muscle function: Improved muscle endurance and strength in older adults 2
  • Cardiovascular biomarkers: Reduced plasma ceramides (validated CVD risk predictors) and improved cardiovascular health markers 4

Important Context

The evidence provided about gout, diabetes, calcium supplementation, and kidney stones (references 5-6) is completely unrelated to urolithin A and should be disregarded when answering this question. These guidelines discuss entirely different compounds and conditions.

Clinical Translation Status

While urolithin A shows promise across multiple systems (cardiovascular 4, neurological 7, musculoskeletal 8), most evidence remains preclinical. However, the safety profile in humans is well-established across multiple independent trials with no serious adverse events reported.

Practical Considerations

  • Bioavailability: Urolithin A is effectively absorbed and reaches target tissues, including crossing the blood-brain barrier 7
  • Dosing: Most human trials used 500-1000 mg/day as the effective dose range 2, 3
  • Duration: Safety confirmed for continuous use up to 4 months; longer-term studies are needed 1

The current evidence strongly supports that urolithin A supplementation is safe for human consumption with no documented harmful effects in clinical trials.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.